Olfactory groove meningioma with a 10-year history of smell loss and olfactory recovery after surgery

Andreas Steenholt Niklassen,1,2 Rasmus Langelund Jørgensen,3 Alexander Wieck Fjaeldstad1,2

SUMMARY
A rare cause of olfactory impairment is olfactory groove meningiomas with insidious onset of non-specific symptoms like headache, olfactory dysfunction, psychiatric symptoms such as depression, personality changes, declining cognitive function, visual disturbances or seizures. A common complication of surgery is loss of olfactory function. Still, the preservation of olfactory function should be attempted as olfactory loss often has a severe negative impact on quality of life. This report describes a woman with an olfactory groove meningioma and a 10-year history of olfactory impairment. It includes preoperatively and postoperatively extended olfactory testing, a neurosurgical approach to preserve the olfactory function and postoperative olfactory rehabilitation. After rehabilitation, the patient regained a normal olfactory function, even though the right-sided olfactory nerve could not be preserved during surgery. The case demonstrates the importance of performing neuroimaging in selected patients with olfactory loss and a method for preserving and potentially improving postoperative olfactory function.

BACKGROUND
Clinical knowledge of how and when to refer patients with olfactory impairment to further investigations is paramount. A rare cause of olfactory impairment is olfactory groove meningiomas (OGM)—representing 5%–18% of intracranial meningiomas.1 The prevalence of pathologically confirmed meningiomas in the USA is 97.5/100 000, with an incidence rate of 8.36 for females and 3.61 for males out of 100 000 person-years.2

OGMs are benign, slow-growing tumours with usually insidious onset of non-specific symptoms like headache, olfactory dysfunction, psychiatric symptoms such as depression, personality changes, declining cognitive function, visual disturbances or seizures.1,14

A common complication of surgery for OGMs is loss of residual or severely impaired olfactory function. However, the preservation of olfactory function should be attempted2 as olfactory loss has a severe negative impact on quality of life.3

This report describes the management of a woman with an OGM and a 10-year history of olfactory impairment. The report includes preoperatively and postoperatively extended olfactory testing with evaluation in a specialised smell and taste clinic, a neurosurgical approach to preserve the olfactory function and postoperative olfactory rehabilitation.

Furthermore, the case demonstrates the importance of performing neuroimaging in selected patients with olfactory loss and a method for preserving and potentially improving postoperative olfactory function in OGM induced olfactory loss.

CASE PRESENTATION
The case presents a fit-and-well 56-year-old woman with a 10-year history of gradually decreasing olfactory function. The patient had 1.5 years previously been diagnosed with stress, and as a result, reduced her work capacity from full time to part time. This stress particularly influenced the patient’s ability for complex processing of tasks at hand, and the patient had to take one subtask at a time. During the previous 6 months, the patient had suffered from intermittent headaches but no history of nausea or vomiting. Our case begins as the patient was admitted to the emergency department with a first-time generalised seizure. Objective examination, including neurological examination, was normal, except for slight suspicion of dysarthria, which resolved.

INVESTIGATIONS
On admission to the emergency department, an acute CT scan followed by a gadolinium-enhanced cerebral MRI was performed. These scans revealed an extra-axial mass on the anterior skull base with extension to the right frontolobe, with homogeneous contrast uptake and significant perilesional oedema (see figure 1). The largest diameter of the mass was 30 mm (see figure 2). A multidisciplinary team conference was conducted with attendings from the neurosurgical, oncological, neurological and neuroradiological departments. Radiologically, the most likely diagnosis was an OGM, and the patient was referred to the neurosurgical department for assessment and treatment. As the tumour was symptomatic with perilesional oedema, informed consent for surgery was obtained. Before the scheduled surgery, the patient was referred to the Flavour smell and taste clinic for preoperative and postoperative examination of the olfactory function. The olfactory function was preoperatively tested with the extended version of the Sniffin’ Sticks2 (Burghart Messtechnik, Wedel, Germany) with a threshold score (T) of 2, discrimination score (D) of 7 and identification score (I) of 11. A total TDI score of 20—indicating severe hyposmia. No other causes of olfactory dysfunction were found.
TREATMENT

Pharmacological

The patient presented with generalised seizures, and antiepileptic medication with lamotrigine was prescribed. Due to increasing headaches and radiologically confirmed substantial white matter changes suggesting oedema, she was supplemented with oral steroids before surgery.

Surgical

Based on the primarily right-sided basofrontal location, the absence of paranasal sinus infiltration and that the patient had intact but diminished olfactory function, a right-sided pterional craniotomy was performed to salvage the olfactory apparatus. Perioperatively, the right olfactory tract was found stretched around the basolateral side of the tumour and could not be preserved. The left olfactory tract was left intact. The tumour was completely resected, and the dural attachment coagulated, corresponding to a Simpson grade II resection.

OUTCOME AND FOLLOW-UP

The immediate postoperative course was uneventful. However, on postoperative day 2, the patient had a generalised tonic-clonic seizure. The postoperative generalised seizure was abolished with intravenous diazepam and an increased dose of prophylactic lamotrigine with no further seizures. An acute CT scan showed expected postoperative changes with minimal blood in the tumour bed. The patient was discharged from the hospital on day three. Histological examination confirmed a benign meningioma. Follow-up contrast MRIs 3 and 12 months postoperatively were without evidence of recurrence, and the oedema had subsided.

Due to complaints of reduced short-term memory and concentration difficulties, the patient was referred for neuropsychological testing and referred to further neurocognitive rehabilitation. Despite rehabilitation, the patient still suffered from reduced working memory and problems handling more complex tasks one year after surgery. Consequently, the patient was not yet able to return to her part-time job.

At the flavour clinic, follow-up was performed 12 months after surgery, where the olfactory function was retested with the extended Sniffin’ Sticks test. The TDI score had improved to 33 (an improvement from 20), with a threshold score of 4, a discrimination score of 14 and an identification score of 15. This reflects a normal olfactory function—a significant improvement from the presurgical olfactory function.

DISCUSSION

Olfactory impairment is prevalent in 15% of the general population. Most patients are diagnosed with an underlying aetiology, but up to 23% remain with no apparent cause and are subsequently classified as idiopathic. Typically, these patients are referred for further investigations with MRI to rule out potentially treatable intracranial disease. However, the hit rate of MRI revealing an underlying treatable central cause of olfactory dysfunction in idiopathic anosmics/hyposmics is as low as 0.08%, according to Rudmik et al. Hoekman et al investigated 130 cases of idiopathic olfactory loss, and only one finding of multiple sclerosis (0.8%) was potentially the cause of olfactory dysfunction. Decker et al investigated 122 cases of idiopathic smell loss and found 31 cases of causal findings for dysosmia. Most of these were due to sinusitis, but two cases of olfactory meningioma were found (1.6%).
This calls for debate whether MRI should be standard practice in idiopathic olfactory loss or be reserved for cases with a higher clinical risk of intracranial disease. A recent study examined a modelling-based economic evaluation of routine MRI for idiopathic olfactory loss. It found that while MRI (US$2400) had a 100% sensitivity in diagnosing intracranial tumours, the no-imaging strategy (US$86) had a 98% sensitivity. The incremental cost per diagnosis for the MRI strategy compared with the no-imaging strategy was US$115669.50. They conclude the most cost-effective strategy is not to perform routine MRI in these patients and that it could be cost-effective in cases when the a priori clinical probability of treatable intracranial disease reaching 7.9%. 

Our case describes the importance of correct diagnostics and treatment for olfactory meningioma and potential good outcome with preservation—and even improvement—of the olfactory function. In the present case, the improvement in olfactory function can most likely be prescribed to reduced oedema on the left side following resection of the right-sided tumour. Preoperatively, the right-sided olfactory function was impaired by the tumour and the left-sided olfactory function by significant oedema. During surgery, the right-sided nerve was not preserved due to tumour growth and had to be removed. This completely removed the right-sided olfactory function post-operatively. After surgery, the oedema diminished, and the left-sided nerve regained normal function. To find the needle in the haystack, it is paramount to identify which symptoms warrant an MRI scan. The most frequent presenting symptoms include mono-symptomatic headache, personality changes, olfactory dysfunction or visual impairment.

In the current case, olfactory dysfunction was present for 10 years, headaches for 6 months and disabling psychiatric stress-related symptoms for 18 months before diagnosis. Using the suggested MRI strategy, the patient should have been correctly diagnosed sooner, which may have reduced the load of cognitive difficulties after surgery. However, further studies are needed to investigate this diagnostic pipeline.

Olfactory dysfunction ranging from hyposmia to complete anosmia is an early symptom of OGMs and found in 58.5%–71.7% of patients with OGMs, but only 6.4%–15% of patients have olfactory dysfunction as their presenting symptom. Extended olfactory testing is not routinely performed in patients with OGMs, and olfactory outcomes following surgery are variably tested and reported. The surgical treatment carries a high risk, up to 89.7%, of decreased or complete loss of olfactory function. However, as the olfactory function is only rarely tested preoperatively and postoperatively, the true incidence of preoperative dysfunction is unknown, and the complication rate of deteriorating olfactory function likely under-reported.

Numerous reports suggest that the risk depends on the surgical approach, with unilateral approaches are more likely to preserve preoperative olfactory function. Besides a higher risk of postoperative anosmia, theclassic bilateral subtotal approach has higher morbidity and mortality than unilateral approaches. Besides the classic trancranial approaches within the last decade, endoscopic endonasal resection of OGM’s through the cribiform plate has been explored as a minimally invasive procedure to reduce surgical morbidity. Even though this technique seems to be advantageous with regards to visual outcome when it comes to olfactory function, this technique carries a higher risk of anosmia as well as postoperative cerebrospinal fluid leak increasing the risk of postoperative meningitis and the need for reoperation.

Gerber et al report on a patient with a large OGM with preoperative anosmia treated with a bifrontal craniotomy and careful dissection of the olfactory tracts. At follow-up, after 15 months,
the patient had regained her sense of smell.21 Also, Bassiouni et al report improving olfactory function in two (4.9%) patients following surgery.4

Our case encourages the use of the pterional approach for OGMs. By preserving the contralateral olfactory tract, preoperative hyposmia can even improve following complete tumour removal. Furthermore, it underlines the need for more studies with thorough preoperative and postoperative olfactory testing to fully uncover the extent of olfactory dysfunction due to OGMs and the potential to improve this overused neurological deficit by choosing the correct surgical approach. In cases where the laterality of remaining olfactory function is uncertain based on neuroimaging, unilateral olfactory testing on both sides can be advantageous.

Twitter Andreas Steenholt Niklassens @AndreasNiklasse

Contributors ASN, AWF and RJL were involved in diagnostics and treatment of the patient. ASN wrote the initial draft of the paper. The patient wrote the patients perspective section and read and approved the paper. All authors revised the paper critically. All authors are guarantors of the paper.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Andreas Steenholt Niklassenn http://orcid.org/0000-0003-4535-127X
Alexander Weick Fjaelldstad http://orcid.org/0000-0002-9135-6920

REFERENCES